El-Najjar Nahed, Jantsch Jonathan, Gessner André
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:57-64. doi: 10.1016/j.jchromb.2017.06.046. Epub 2017 Jun 27.
A simple and fast ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the analysis of Fosfomycin in different matrices (human plasma/urine, and aqueous fluid) has been established and validated. Sample cleanup consists, depending on the matrix used, on protein precipitation or dilution with methanol containing isotopically labeled Fosfomycin as internal standard. Compounds, separated on a Luna Omega PS C column, were detected in multiple reactions monitoring in negative ion mode using API4000 system. With a total run time of 2min and using low volume of samples (plasma: 10μl, urine: 2μl, and aqueous fluid: 5μl), the covered ranges were: plasma (12.5-800μg/mL), urine (62.5-4000μg/mL), and aqueous fluid (1-160μg/mL). The method proved to be precise and accurate. The inaccuracy and imprecision in each matrix at the four tested quality controls including the lower limit of quantification were:: plasma (≤ 6.5%, ≤ 8%), urine (≤ 5.8%, ≤ 6.3%), and aqueous fluid (≤ 10.6%, ≤12%). The method is fast and robust which makes it relevant for pharmacokinetic studies and therapeutic drug monitoring. The appropriateness of the developed method in clinical application is also confirmed.
已建立并验证了一种简单快速的超高效液相色谱串联质谱法(UPLC-MS/MS),用于分析不同基质(人血浆/尿液和水性液体)中的磷霉素。根据所用基质的不同,样品净化包括用含有同位素标记的磷霉素作为内标的甲醇进行蛋白质沉淀或稀释。在Luna Omega PS C柱上分离的化合物,使用API4000系统在负离子模式下通过多反应监测进行检测。总运行时间为2分钟,使用少量样品(血浆:10μl,尿液:2μl,水性液体:5μl),覆盖范围为:血浆(12.5 - 800μg/mL),尿液(62.5 - 4000μg/mL),水性液体(1 - 160μg/mL)。该方法被证明是精确且准确的。在包括定量下限在内的四个测试质量控制下,每种基质的不准确度和不精密度分别为:血浆(≤ 6.5%,≤ 8%),尿液(≤ 5.8%,≤ 6.3%),水性液体(≤ 10.6%,≤ 12%)。该方法快速且稳健,这使其适用于药代动力学研究和治疗药物监测。所开发方法在临床应用中的适用性也得到了证实。